# Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients

> **NCT03927144** · PHASE4 · COMPLETED · sponsor: **Amgen** · enrollment: 621 (actual)

## Conditions studied

- Episodic Migraine

## Interventions

- **DRUG:** AMG334
- **DRUG:** Oral Prophylactic

## Key facts

- **NCT ID:** NCT03927144
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-15
- **Primary completion:** 2021-10-01
- **Final completion:** 2022-09-30
- **Target enrollment:** 621 (ACTUAL)
- **Last updated:** 2023-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03927144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03927144, "Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT03927144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*